Focus on HIV Care

Back to articles

Nevirapine, Efavirenz Mostly Equivalent as Single Agents

KEY POINT

In a head-to-head comparison, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine (Viramune—Boehringer Ingelheim) and efavirenz (Sustiva—GlaxoSmithKline) were equivalent from an effectiveness standpoint, but more cases of hepatotoxicity tarnished results with nevirapine given once rather than twice daily. Combination treatment with both agents produced higher dropout rates because of adverse effects, leading investigators to conclude that the two NNRTIs should not be administered concomitantly.

SOURCES

van Leth F et al., for the 2NN study group. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Presented at: Conference on Retroviruses and Opportunistic Infections; Boston, Mass.; February 14, 2003. 

Moyle GJ. Expert commentary: 2NN or not 2NN? What is the answer? Accessed March 6, 2003. http://www.medscape.com.